AVL-3288
AVL-3288 is a first-in-class, orally available, small molecule, selective allosteric modulator of the alpha7 nicotinic acetylcholine receptor (α7 nAChR). AVL-3288 has shown preclinical efficacy in rat paradigms of attention and memory, including models of cognitive dysfunction1-3. AVL-3288 evokes positive modulation of acetylcholine (ACh)-induced EC5 currents (EC50 = 0.7 μM). AVL-3288 exhibits cognitive-enhancing properties in rodent models; displays no cytotoxic effects in PC12 cells or rat primary cortical neurons.
| Supplier | Ace Therapeutics |
|---|---|
| Product # | SMD455 |
| CAS # | 917837-54-8 |
| Pricing | Customizable size, Inquiry |
| Synonym | AVL-3288; AVL 3288; AVL3288; XY-4083; XY 4083; XY4083; Anvylic-3288; UCI-4083; UCI4083; UCI 4083; CCMI. |
| Product Category | Lab-use Small Molecule Drugs |
| Chemical Formula | C19H15Cl2N3O2 |
| Exact Mass | 387.0541 |
| Molecular Weight | 388.248 |
| Elemental Analysis | C, 58.78; H, 3.89; Cl, 18.26; N, 10.82; O, 8.24 |
| IUPAC/Chemical Name | (Z)-3-(4-Chloroanilino)-N-(4-chlorophenyl)-2-(3-methylisoxazol-5-yl)prop-2-enamide |
| InChi Key | VMAKIACTLSBBIY-BOPFTXTBSA-N |
| InChi Code | InChI=1S/C19H15Cl2N3O2/c1-12-10-18(26-24-12)17(11-22-15-6-2-13(20)3-7-15)19(25)23-16-8-4-14(21)5-9-16/h2-11,22H,1H3,(H,23,25)/b17-11- |
| SMILES Code | O=C(NC1=CC=C(Cl)C=C1)/C(C2=CC(C)=NO2)=C\NC3=CC=C(Cl)C=C3 |
| Appearance | Solid powder |
| Purity | >98% (or refer to the Certificate of Analysis) |
| Shipping Condition | Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs. |
| Storage Condition | Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years). |
| Solubility | Soluble in DMSO |
| Shelf Life | >2 years if stored properly |
| Drug Formulation | This drug may be formulated in DMSO |
| Stock Solution Storage | 0 - 4℃ for short term (days to weeks), or -20℃ for long term (months). |
| HS Tariff Code | 2934.99.9001 |
| Class-2 | Schizophrenia |
| Availability | 2 Weeks |